Compare Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Sht-Term Inflation-Protected Sec Idx ETF vs Zimmer Biomet Holdings Inc — how do they compare? Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.45 (market cap $73.20B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.88B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 4.3× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| VTIP | ZBH | |
|---|---|---|
Market Cap | $73.20B | $16.88B |
Volume | 2,480,668 | 1,991,354 |
52-Week High | $50.46 | $103.98 |
52-Week Low | $48.38 | $79.58 |
Typical Hold Time | 91 Days | 89 Days |
Sector | — | Health |
Enterprise Value | — | $23.95B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VTIP trades at $48.46, up 0.08% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The ETF, focused on short-term inflation-protected securities, shows strong institutional interest, with firms like NewEdge Advisors increasing positions by 45.5% in Q2 2026 (SEC filing, September 2026). Recent news highlights its role in hedging inflation amid rising energy prices and Fed rate hikes.
The outlook for VTIP is supported by its inflation-hedging appeal in a high-rate environment, but risks include interest rate sensitivity and competition from other TIPS ETFs. Wall Street sentiment is cautious yet constructive, given its low-cost structure and short-duration focus, positioning it as a defensive allocation for investors seeking inflation protection without significant rate risk.
Zimmer Biomet (ZBH) trades at $88.91, down 0.86% on the day, with a bearish technical signal from moving averages. The company reported revenue of $8.23B in 2025, with net income of $705.1M, and has beaten EPS estimates for the last three quarters. Recent news highlights a quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The outlook is mixed: strong fundamentals and consistent earnings beats support growth, but technical indicators and rising debt-to-asset ratios pose risks. Analyst consensus suggests a 16% upside to the $103.11 price target, though nearly half of analysts recommend Hold. Key risks include competitive pressures and execution of the company's strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
